Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000139.xml
Notfallmedizin up2date 2020; 15(01): 39-55
DOI: 10.1055/a-0963-1427
DOI: 10.1055/a-0963-1427
Internistische Notfälle
Diagnose und Therapie des kardiogenen Schocks im akuten Myokardinfarkt
Further Information
Publication History
Publication Date:
28 February 2020 (online)
Der kardiogene Schock ist weiterhin neben malignen Herzrhythmusstörungen die für die Prognose relevanteste Komplikation des akuten Myokardinfarkts mit einer Mortalität von 40 – 50%. Dieser Artikel soll das Thema von der Diagnose bereits in der prähospitalen Phase über die akute Triage bis zur Therapie beleuchten.
Kernaussagen
-
Die Mortalität beim kardiogenen Schock liegt bei 40 – 50%. Rund 80% der kardiogenen Schocks basieren auf einem akuten Myokardinfarkt. Etwa 5 – 15% aller Myokardinfarkte entwickeln einen kardiogenen Schock.
-
Die Verdachtsdiagnose „kardiogener Schock“ kann bereits beim ersten Patientenkontakt mittels EKG, Blutdruckmessung, Anamnese und klinischer Untersuchung gestellt werden.
-
Bei Patienten mit infarktbedingtem kardiogenem Schock sollten unverzüglich eine invasive Koronardiagnostik mit anschließender Revaskularisation durchgeführt werden.
-
Eine frühe Diagnose sowie ein zeitnaher Transport in ein Krankenhaus der maximalen Versorgung und eine frühe Revaskularisation mittels PCI oder ggf. CABG ist für die weitere Prognose des Patienten von entscheidender Bedeutung.
-
Zur hämodynamischen Stabilisierung sind Dobutamin und Noradrenalin die Mittel der 1. Wahl. Die Dosierung sollte immer so niedrig wie möglich gewählt werden.
-
Linksventrikuläre Unterstützungssysteme können im therapierefraktären kardiogenen Schock in Zentren implantiert werden. Implantationszeitpunkt, Art des Device und prognostischer Nutzen sind aktuell noch Untersuchungsschwerpunkte einiger Studien.
-
Literatur
- 1 De Luca L, Olivari Z, Farina A. et al. Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes. Eur J Heart Fail 2015; 17: 1124-1132 doi:10.1002/ejhf.339
- 2 Kolte D, Khera S, Aronow WS. et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc 2014; 3: e000590 doi:10.1161/JAHA.113.000590
- 3 Backhaus T, Fach A, Schmucker J. et al. Management and predictors of outcome in unselected patients with cardiogenic shock complicating acute ST-segment elevation myocardial infarction: results from the Bremen STEMI Registry. Clin Res Cardiol 2018; 107: 371-379 doi:10.1007/s00392-017-1192-0
- 4 Shah M, Patnaik S, Patel B. et al. Trends in mechanical circulatory support use and hospital mortality among patients with acute myocardial infarction and non-infarction related cardiogenic shock in the United States. Clin Res Cardiol 2018; 107: 287-303 doi:10.1007/s00392-017-1182-2
- 5 Hunziker L, Radovanovic D, Jeger R. et al. Twenty-year trends in the incidence and outcome of cardiogenic shock in AMIS Plus Registry. Circulat Cardiovasc Intervent 2019; 12: e007293 doi:10.1161/circinterventions.118.007293
- 6 Rathod KS, Koganti S, Iqbal MB. et al. Contemporary trends in cardiogenic shock: Incidence, intra-aortic balloon pump utilisation and outcomes from the London Heart Attack Group. Eur Heart J Acute Cardiovasc Care 2018; 7: 16-27 doi:10.1177/2048872617741735
- 7 Harjola VP, Lassus J, Sionis A. et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail 2015; 17: 501-509 doi:10.1002/ejhf.260
- 8 Thiele H, Akin I, Sandri M. et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 2017; 377: 2419-2432 doi:10.1056/NEJMoa1710261
- 9 Thiele H, Zeymer U, Neumann FJ. et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367: 1287-1296 doi:10.1056/NEJMoa1208410
- 10 Werdan K RM, Buerke M, Engelmann L. et al. Deutsch-Österreichische S3-Leitlinie Infarktbedingter kardiogener Schock. Diagnose, Monitoring und Therapie. Kardiologe 2011; 5: 166-224
- 11 Werdan K, Ruß M, Boeken U. et al. Deutsch-österreichische S3 Leitlinie „Infarktbedingter kardiogener Schock – Diagnose, Monitoring und Therapie“, 2. Aufl. Registernummer 019-013, Stand: 28.02.2019. Im Internet: https://www.awmf.org/leitlinien/detail/ll/019-013.html Stand: 02.01.2020
- 12 van Diepen S, Katz JN, Albert NM. et al. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation 2017; 136: e232-e268 doi:10.1161/CIR.0000000000000525
- 13 Barton M, Gruntzig J, Husmann M. et al. Balloon angioplasty – the legacy of Andreas Gruntzig, M.D. (1939–1985). Front Cardiovasc Med 2014; 1: 15 doi:10.3389/fcvm.2014.00015
- 14 Hochman JS, Sleeper LA, Webb JG. et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295: 2511-2515 doi:10.1001/jama.295.21.2511
- 15 Shiraki H, Yokozuka H, Negishi K. et al. Acute impact of right ventricular infarction on early hemodynamic course after inferior myocardial infarction. Circ J 2010; 74: 148-155 doi:10.1253/circj.cj-09-0405
- 16 Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008; 117: 686-697 doi:10.1161/CIRCULATIONAHA.106.613596
- 17 Post H, Schwarzl M, Steendijk P. et al. Coronary microembolisation induces acute and progressive diastolic heart failure. Eur Heart J 2010; 31: 44
- 18 Baran DA, Grines CL, Bailey S. et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Cathet Cardiovasc Intervent 2019; 94: 29-37 doi:10.1002/ccd.28329
- 19 Thiele H, Ohman EM, de Waha-Thiele S. et al. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J 2019; 40: 2671-2683 doi:10.1093/eurheartj/ehz363
- 20 Eikelboom JW, Mehta SR, Anand SS. et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782 doi:10.1161/CIRCULATIONAHA.106.612812
- 21 Rao SV, Jollis JG, Harrington RA. et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555-1562 doi:10.1001/jama.292.13.1555
- 22 Thiele H, Allam B, Chatellier G. et al. Shock in acute myocardial infarction: the Cape Horn for trials?. Eur Heart J 2010; 31: 1828-1835 doi:10.1093/eurheartj/ehq220
- 23 Sommer P, Fürnau G, Thiele H. EKG-Diagnostik. Notfallmed up2date 2010; 5: 193-208
- 24 Ibanez B, James S, Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119-177 doi:10.1093/eurheartj/ehx393
- 25 Fuernau G, Thiele H. The spectrum of haemodynamic support in cardiogenic shock: how to choose and use. Kardiol Polsk 2013; 71: 887-892
- 26 Bernard SA, Gray TW, Buist MD. et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002; 346: 557-563 doi:10.1056/NEJMoa003289
- 27 Hochman JS, Sleeper LA, Webb JG. et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock?. N Engl J Med 1999; 341: 625-634 doi:10.1056/NEJM199908263410901
- 28 Investigators T, Alexander JH, Reynolds HR. et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007; 297: 1657-1666 doi:10.1001/jama.297.15.joc70035
- 29 Fincke R, Hochman JS, Lowe AM. et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44: 340-348 doi:10.1016/j.jacc.2004.03.060
- 30 Kubiak GM, Tomasik AR, Bartus K. et al. Lactate in cardiogenic shock – current understanding and clinical implications. J Physiol Pharmacol 2018; 69: 15-21 doi:10.26402/jpp.2018.1.02
- 31 Fuernau G, Poenisch C, Eitel I. et al. Prognostic impact of established and novel renal function biomarkers in myocardial infarction with cardiogenic shock: A biomarker substudy of the IABP-SHOCK II-trial. Int J Cardiol 2015; 191: 159-166 doi:10.1016/j.ijcard.2015.04.242
- 32 Jung C, Fuernau G, Eitel I. et al. Incidence, laboratory detection and prognostic relevance of hypoxic hepatitis in cardiogenic shock. Clin Res Cardiol 2017; 106: 341-349 doi:10.1007/s00392-016-1060-3
- 33 Asfar P, Meziani F, Hamel JF. et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med 2014; 370: 1583-1593 doi:10.1056/NEJMoa1312173
- 34 Ameloot K, De Deyne C, Eertmans W. et al. Early goal-directed haemodynamic optimization of cerebral oxygenation in comatose survivors after cardiac arrest: the Neuroprotect post-cardiac arrest trial. Eur Heart J 2019; 40: 1804-1814 doi:10.1093/eurheartj/ehz120
- 35 Werdan K, Ruß M, Buerke M. et al. Deutsch-Österreichische S3-Leitlinie Infarktbedingter kardiogener Schock. Diagnose, Monitoring und Therapie. Kardiologe 2011; 5: 166-224
- 36 Hochman JS, Sleeper LA, White HD. et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190-192 doi:10.1001/jama.285.2.190
- 37 Thiele H, Zeymer U, Neumann FJ. et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013; 382: 1638-1645 doi:10.1016/S0140-6736(13)61783-3
- 38 Thiele H, Akin I, Sandri M. et al. One-Year Outcomes after PCI Strategies in Cardiogenic Shock. N Engl J Med 2018; 379: 1699-1710 doi:10.1056/NEJMoa1808788
- 39 Neumann FJ, Sousa-Uva M, Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87-165 doi:10.1093/eurheartj/ehy394
- 40 Wang TY, Nallamothu BK, Krumholz HM. et al. Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. JAMA 2011; 305: 2540-2547 doi:10.1001/jama.2011.862
- 41 Scholz KH, Maier SKG, Maier LS. et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. Eur Heart J 2018; 39: 1065-1074 doi:10.1093/eurheartj/ehy004
- 42 Levy B, Clere-Jehl R, Legras A. et al. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol 2018; 72: 173-182 doi:10.1016/j.jacc.2018.04.051
- 43 De Backer D, Biston P, Devriendt J. et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362: 779-789 doi:10.1056/NEJMoa0907118
- 44 Fuhrmann JT, Schmeisser A, Schulze MR. et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008; 36: 2257-2266 doi:10.1097/CCM.0b013e3181809846
- 45 Gordon AC, Perkins GD, Singer M. et al. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. N Engl J Med 2016; 375: 1638-1648 doi:10.1056/NEJMoa1609409
- 46 Antcliffe DB, Santhakumaran S, Orme RML. et al. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. Intensive Care Med 2019; 45: 1392-1400 doi:10.1007/s00134-019-05731-w
- 47 Droppa M, Vaduganathan M, Venkateswaran RV. et al. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. Resuscitation 2019; 137: 205-212 doi:10.1016/j.resuscitation.2019.02.008
- 48 Steg PG, van ʼt Hof A, Hamm CW. et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369: 2207-2217 doi:10.1056/NEJMoa1311096
- 49 Valgimigli M, Frigoli E, Leonardi S. et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015; 373: 997-1009 doi:10.1056/NEJMoa1507854
- 50 van Diepen S, Reynolds HR, Stebbins A. et al. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. Crit Care Med 2014; 42: 281-288 doi:10.1097/CCM.0b013e31829f6242
- 51 Thiele H, Jobs A, Ouweneel DM. et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 2017; 38: 3523-3531 doi:10.1093/eurheartj/ehx363
- 52 Prondzinsky R, Unverzagt S, Russ M. et al. Hemodynamic effects of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP shock trial. Shock 2012; 37: 378-384 doi:10.1097/SHK.0b013e31824a67af
- 53 Thiele H, Zeymer U, Thelemann N. et al. intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABP-SHOCK II Trial. Circulation 2018; 139: 395-403 doi:10.1161/CIRCULATIONAHA.118.038201
- 54 Van de Werf F, Bax J, Betriu A. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945 doi:10.1093/eurheartj/ehn416
- 55 Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619 doi:10.1093/eurheartj/ehs215
- 56 Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200 doi:10.1093/eurheartj/ehw128
- 57 Kawashima D, Gojo S, Nishimura T. et al. Left ventricular mechanical support with impella provides more ventricular unloading in heart failure than extracorporeal membrane oxygenation. ASAIO J 2011; 57: 169-176 doi:10.1097/MAT.0b013e31820e121c
- 58 Schrage B, Ibrahim K, Loehn T. et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation 2019; 139: 1249-1258 doi:10.1161/CIRCULATIONAHA.118.036614
- 59 Becher PM, Schrage B, Sinning CR. et al. Venoarterial extracorporeal membrane oxygenation for cardiopulmonary support. Circulation 2018; 138: 2298-2300 doi:10.1161/CIRCULATIONAHA.118.036691
- 60 Udesen NJ, Moller JE, Lindholm MG. et al. Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. Am Heart J 2019; 214: 60-68 doi:10.1016/j.ahj.2019.04.019
- 61 Karami M, den Uil CA, Ouweneel DM. et al. Mechanical circulatory support in cardiogenic shock from acute myocardial infarction: Impella CP/5.0 versus ECMO. Eur Heart J Acute Cardiovasc Care 2019; DOI: 10.1177/2048872619865891.
- 62 Menon V, Fincke R. Cardiogenic shock: a summary of the randomized SHOCK trial. Congest Heart Fail 2003; 9: 35-39
- 63 Donnino MW, Andersen LW, Berg KM. et al. Temperature management after cardiac arrest: an advisory statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation and the American Heart Association Emergency Cardiovascular Care Committee and the Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Resuscitation 2016; 98: 97-104 doi:10.1016/j.resuscitation.2015.09.396
- 64 Soar J, Callaway CW, Aibiki M. et al. Part 4: Advanced life support: 2015 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Resuscitation 2015; 95: e71-e120 doi:10.1016/j.resuscitation.2015.07.042
- 65 Jacobshagen C, Pelster T, Pax A. et al. Effects of mild hypothermia on hemodynamics in cardiac arrest survivors and isolated failing human myocardium. Clin Res Cardiol 2010; 99: 267-276 doi:10.1007/s00392-010-0113-2
- 66 Gotberg M, van der Pals J, Olivecrona GK. et al. Mild hypothermia reduces acute mortality and improves hemodynamic outcome in a cardiogenic shock pig model. Resuscitation 2010; 81: 1190-1196 doi:10.1016/j.resuscitation.2010.04.033
- 67 Schwarzl M, Huber S, Maechler H. et al. Left ventricular diastolic dysfunction during acute myocardial infarction: effect of mild hypothermia. Resuscitation 2012; 83: 1503-1510 doi:10.1016/j.resuscitation.2012.05.011
- 68 Fuernau G, Beck J, Desch S. et al. Mild hypothermia in cardiogenic shock complicating myocardial infarction. Circulation 2019; 139: 448-457 doi:10.1161/circulationaha.117.032722
- 69 Eitel C, Gaspar T, Bode K. et al. Temporary left ventricular stimulation in patients with refractory cardiogenic shock and asynchronous left ventricular contraction: a safety and feasibility study. Heart Rhythm 2013; 10: 46-52 doi:10.1016/j.hrthm.2012.09.007